Clinical trial NCT06628297: Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.
Official title: Small Vessel Disease of the Brain and Heart a PET Perfusion Study of Training Effects
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Microvascular Disease
Microvascular Complications
Dementia
Diabetes Mellitus Type 2
Cerebral Hypoperfusion
Keywords: microvascular disease
microvascular complications of the heart
microvascular complications of the brain
diabetes type 2
dementia
microvascular disease patophysiology
Lead sponsor: University Hospital Bispebjerg and Frederiksberg
Sponsor class: OTHER
Collaborators: name: Danish Cardiovascular Academy
name: Bispebjerg Hospital
name: The Dagmar Marshall Foundation
name: Steno Diabetes Center Copenhagen
First posted: 2024-10-04
Enrollment: 72
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 2 diabetes with increased risk of microvascular disease.

Brief summary: In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.

It has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.

Among other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.

Exercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions.

Systemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max).

Detailed description: The goal of this clinical trial is to compare baseline measurements relevant to microvascular disease between patients with diabetes and increased risk of microvascular disease with healthy age-matched control.

The researchers wish to examine if small vessel disease is a disease that affects several organs at once in the same individuals by examining it in the brain and heart in the same participants. The researchers will also test if cardiorespiratory conditioning (VO2-max), blood perfusion to the heart and brain and cognitive performance are correlated in patients with microvascular disease.

To adress these aims the researchers have defined the following assumptions that they will refute or confirm through this study:

* Patients with type 2 diabetes and increased risk of small vessel disease have significantly reduced perfusion capacity of the brain and heart compared to healthy controls as part of a multisystem disease
* Perfusion capacity of the brain and heart, the cardiorespiratory fitness level of the subjects and cognitive performance are directly linked.

  48 patients with diabetes and 24 healthy age-matched controls will undergo baseline testing that include:
* Cardiopulmonal Exercise Test (CPET) to determine cardiopulmonal conditioning (VO2-max)
* Isometric knee strength (if logistically possible)
* Echocardiography
* Blood perfusion capacity of the heart and brain via \[15O\]H2O-PET scans
* Brain MRI to determine structural damages
* Blood samples for basic health check (relevant to inclusion, exclusion and safety) and blood samples looking at endothelial and neurological damage for a biobank
* Cognitive testing (SCIP-D and CANTAB)

Afterwards the researchers will compare the results between the two groups and see if there is a correlation between VO2-max, blood perfusion to the heart and brain and cognitive performance.

Eligibility criteria: Inclusion Criteria for the patients with type 2 diabetes:

Diabetes type II diagnose with one of the following:

* Duration over 5 years
* Moderate microalbuminuria
* Non-proliferative diabetic retinopathy

  * Speaks and understands Danish (required for reliable cognitive testing)
  * Able to provide informed and written consent

Exclusion Criteria or the patients with type 2 diabetes:

Moderate to high intensity training \&gt;1 times/week.

* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \&lt;45%), asthma.
* Previous stroke or significant neurological disease including cognitive dysfunction.
* Ongoing depression.
* Hypothyroidism
* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

Inclusion Criteria for the healthy age-matched controls:

* Age \&gt; 60 years
* No diagnosis of T2D according to WHO\&#39;s criteria.
* Speaks and understands Danish (required for reliable cognitive testing)
* Able to provide informed and written consent

Exclusion Criteria for the healthy age-matched controls:

* Moderate to high intensity training \&gt;2 times/week.
* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \&lt;45%), asthma.
* Previous stroke or significant neurological disease including cognitive dysfunction.
* Ongoing depression.
* Hypothyroidism
* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

Primary outcomes:
measure: [15O]H2O PET assessment of the blood perfusion to the brain
timeFrame: From baseline testing to end of study, 6 months
measure: [15O]H2O PET assessment of the blood perfusion of the heart
timeFrame: From baseline testing to end of study, 6 months
Secondary outcomes:
measure: Cognitive performance (CANTAB)
timeFrame: From baseline testing to end of study, 6 months
measure: Cognitive Performance (SCIP-D)
timeFrame: From baseline testing to end of study, 6 months
measure: Cardiorespiratory fitness (VO2-max)
timeFrame: From baseline testing to end of study, 6 months
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg and Frederiksberg Hospital
Study officials:
affiliation: University Hospital Bispebjerg and Frederiksberg
name: Thomas EHJ Primary Investigator, Medical Doctor
role: PRINCIPAL_INVESTIGATOR
References: